Bioventus annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Bioventus R&D Spending Growth & History (BVS)
Bioventus's r&d spending was $12.1M for fiscal 2025.
View full Bioventus company overviewBioventus annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.1M | −$1.8M | −13.17% |
| 2024 | 2024-12-31 | $14.0M | $505,000 | +3.76% |
| 2023 | 2023-12-31 | $13.4M | −$10.4M | −43.63% |
| 2022 | 2022-12-31 | $23.9M | $4.8M | +25.29% |
| 2021 | 2021-12-31 | $19.0M | $7.8M | +69.96% |
| 2020 | 2020-12-31 | $11.2M | $147,000 | +1.33% |
| 2019 | 2019-12-31 | $11.1M | — | — |
Bioventus quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-27 | $3.2M | $1,000 | +0.03% |
| Q1 2026 | 2026-03-28 | $2.5M | −$544,000 | −18.07% |
| Q4 2025 | 2025-12-31 | $3.0M | −$264,000 | −8.07% |
| Q3 2025 | 2025-09-27 | $2.9M | −$920,000 | −23.94% |
| Q2 2025 | 2025-06-28 | $3.2M | −$1.0M | −24.66% |
| Q1 2025 | 2025-03-29 | $3.0M | $384,000 | +14.62% |
| Q4 2024 | 2024-12-31 | $3.3M | $9,000 | +0.28% |
| Q3 2024 | 2024-09-28 | $3.8M | $828,000 | +27.46% |
| Q2 2024 | 2024-06-29 | $4.2M | $812,000 | +23.90% |
| Q1 2024 | 2024-03-30 | $2.6M | −$1.1M | −30.34% |
| Q4 2023 | 2023-12-31 | $3.3M | −$2.7M | −45.14% |
| Q3 2023 | 2023-09-30 | $3.0M | −$1.6M | −34.66% |
| Q2 2023 | 2023-07-01 | $3.4M | −$3.0M | −46.62% |
| Q1 2023 | 2023-04-01 | $3.8M | −$3.2M | −45.57% |
| Q4 2022 | 2022-12-31 | $5.9M | −$1.2M | −16.29% |
| Q3 2022 | 2022-10-01 | $4.6M | −$1.5M | −25.01% |
| Q2 2022 | 2022-07-02 | $6.4M | $1.5M | +31.64% |
| Q1 2022 | 2022-04-02 | $6.9M | $6.0M | +631.57% |
| Q4 2021 | 2021-12-31 | $7.1M | $4.2M | +145.69% |
| Q3 2021 | 2021-10-02 | $6.2M | $2.6M | +72.40% |
| Q2 2021 | 2021-07-03 | $4.8M | $2.2M | +86.29% |
| Q1 2021 | 2021-04-03 | $947,000 | −$1.2M | −55.87% |
| Q4 2020 | 2020-12-31 | $2.9M | — | — |
| Q3 2020 | 2020-09-26 | $3.6M | — | — |
| Q2 2020 | 2020-06-27 | $2.6M | — | — |
| Q1 2020 | 2020-03-28 | $2.1M | — | — |
Bioventus r&d spending trends
Over the last five fiscal years, Bioventus's r&d spending increased from $11.2M to $12.1M, a change of $911,000. The latest reported quarter, Q2 2026, shows $3.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioventus source filings ↗